Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

3 Best Stocks to Buy and Hold for a Lifetime

With inflation still alarmingly high, the Fed is poised to raise interest rates further. This is predicted to keep the stock market volatile. Amid this, investors should focus on their long-term strategies and buy fundamentally strong stocks Visa (V), Pfizer (PFE), and Molina Healthcare (MOH), which have solid growth potential.…

StockNews.com

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer buys biotech firm Seagen for $43 billion

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

Bangkok Post

What the research shows about risks of myocarditis from COVID vaccines versus risks of heart damage from COVID – two pediatric cardiologists explain how to parse the data

Soon after the first COVID-19 vaccines appeared in 2021, reports of rare cases of heart inflammation, or myocarditis, began to surface.

The Conversation

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

The Independent UK

A New Universal Covid-19 Vaccine Could Stop Future Variants in Their Tracks

Here's How a New Covid-19 Vaccine Might Protect Us Against Future Variants

Inverse

Read news from The Economist, FT, and more,
with one subscription

FDA approves world’s first fast-acting nasal spray to treat migraines

Drug marks ‘significant breakthrough’ for people with migraine who need freedom from pain

The Independent UK

Pfizer receives FDA approval for migraine nasal spray, claims pain relief in 15 minutes

The U.S. Food and Drug Administration has approved a nasal spray developed by Pfizer as a means to quickly treat the painful symptoms associated with suffering a migraine.

Tribune News Service

Greater Manchester's new Covid hotspots revealed as figures show how many in hospital have virus

Around one in 14 of the region's hospital beds are currently occupied by patients with coronavirus

Manchester Evening News

Date confirmed for final Covid vaccines before NHS ends universal offer for good

Health and Social Care Secretary Steve Barclay made the announcement on Wednesday

Manchester Evening News

Moderna's COVID vaccine gambit: Hike the price, offer free doses for uninsured

Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.

WEKU

What is the UK’s Covid-19 spring booster programme and who is eligible for a vaccine?

London is still lagging behind parts of the country in terms of the vaccine uptake

Evening Standard

Vulnerable people in UK to be offered spring Covid booster vaccine

Those eligible are being urged to come forward for the jab as infections remain high across UK

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Covid booster vaccine to be offered to elderly and vulnerable

People aged 75 and over will be offered a vaccination, along with care home residents and anyone aged five and over who is immunosuppressed

Manchester Evening News

Spring Covid-19 booster to be rolled out to vulnerable and elderly

Boosters will be offered around six months on from the previous winter dose

Wales Online

Some people to be offered another Covid booster jab

Over 75s and some under 12s are on the list

The Independent UK

Elderly and vulnerable to be offered spring Covid booster jab

People aged 75 and over will be offered a vaccination, along with care home residents and anyone aged five and over who is immunosuppressed.

Get all your
news in one place.

100's of premium titles.
One news app.

ABC News

Former RAA employee Susan Clarke convicted and fined for COVID-19 vaccination fraud

An Adelaide woman who exploited a vulnerable person to have a COVID-19 vaccination in her name to keep her job has been fined nearly $8,000 for her crime, with the sentencing judge describing her conduct as "reprehensible".

Fortune

An FDA panel has recommended a 2-dose RSV vaccine for older Americans. Here’s when they might be able to get it

The jabs could be ready as soon as this summer, one expert tells Fortune.

Daily Mirror

Laurence Fox's GB News show struck by Ofcom complaints over Covid pregnancy claims

GB News came under fire from viewers over an interview in which Dr Tina Peers claimed 58% of women suffered a miscarriage during the Pfizer Covid vaccine trial

Fortune

Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It's a market that will be worth up to $10 billion in a decade

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

The Independent UK

FDA panel narrowly backs Pfizer RSV vaccine for older adults

Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV

Tribune News Service

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

StockNews.com

1 High-Value Stock to Keep in Your Portfolio Forever

Pfizer (PFE) reported record-breaking revenue and earnings for fiscal 2022. Furthermore, the combination of expected launches and additional pipeline products position the company for continued robust growth through the rest of this decade and beyond. Amid a volatile macro environment, investing in this high-value stock for the long term could…

1 … 27 28 29 30

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.